Report Overview

An increasing focus on the diagnosis, treatment, and management of rising prevalence of chronic and genetic diseases is expected to boost the growth of North America Genomic Testing Market during the forecast period between 2026 and 2032.

North America Genomic Testing Market – Industry Trends & Forecast Report, 2032

North America Genomic Testing Market size was estimated at USD 10.56 billion in 2025. During the forecast period between 2026 and 2032, North America Genomic Testing Market size is projected to grow at a CAGR of 14.62% reaching a value of USD 27.45 billion by 2032. Prominent growth drivers of North America Genomic Testing Market include the growing adoption of precision medicine, particularly in oncology, where genomic profiling guides diagnosis, treatment selection, and monitoring. Advances in next‑generation sequencing (NGS) and bioinformatics have dramatically reduced turnaround times and costs, enabling large gene panels, whole‑exome, and whole‑genome sequencing to move from research into routine clinical practice. This technological progress, coupled with clear clinical utility for targeted therapies and immunotherapies, has prompted clinicians and health systems to integrate genomic tests into care pathways for cancer, rare diseases, and pharmacogenomics, increasing test volumes.

Genomic Testing – Overview

Genomic testing examines an individual’s DNA or RNA to identify genetic variants that influence disease risk, diagnosis, prognosis, and treatment response. It spans a range of technologies from targeted single‑gene tests and microarrays to next‑generation sequencing (NGS) approaches, such as gene panels, whole‑exome sequencing (WES), and whole‑genome sequencing (WGS), and applications including oncology profiling, hereditary disease diagnosis, newborn screening, carrier screening, pharmacogenomics, and infectious disease pathogen sequencing. Tests can be ordered by clinicians, performed in specialized laboratories, or accessed direct‑to‑consumer (for select indications), and are supported by bioinformatics pipelines that translate raw sequence data into clinically actionable reports.

North America Genomic Testing Market

Growth Drivers

Adoption of Precision Medicine in Oncology Therapy

Precision medicine in oncology uses genomic profiling to match patients with therapies that target the specific molecular drivers of their tumors, and this shift toward biomarker‑driven care is a primary growth engine of North America Genomic Testing Market. Comprehensive panels, whole‑exome, and increasingly whole‑genome sequencing identify actionable mutations, fusions, copy‑number changes, and mutational signatures that inform selection of targeted agents, eligibility for immunotherapy (tumor mutational burden and MSI status), and enrollment in genotype‑guided clinical trials. Beyond initial therapy selection, genomic assays enable monitoring of minimal residual disease (MRD) through sensitive circulating tumor DNA (ctDNA) tests, which can detect relapse earlier than conventional imaging and support treatment escalation or de‑escalation decisions.

Challenges

Limited Number of Professionals with Expertise

North America Genomic Testing Market faces a pronounced shortage of skilled workforce and clinical expertise that limits timely access and quality of care. There are too few genetic counselors, clinical geneticists, molecular laboratorians, and bioinformaticians to keep pace with rising test volumes and increasingly complex results; this bottleneck causes longer turnaround times, inconsistent interpretation of variants, and reduced capacity for patient counseling and cascade testing. At the same time, many frontline clinicians lack training in genomics, when to order tests, how to interpret reports, and how to act on findings, leading to underuse, inappropriate testing, or mismanagement. The gap is exacerbated by competition for specialized talent from tech and pharma, uneven geographic distribution (with rural and community providers particularly underserved), and limited training pipelines, making scalable solutions like tele-genetics, AI-assisted interpretation, and expanded education essential to meet demand.

Impact of Escalating Geopolitical Tensions on North America Genomic Testing Market

Escalating geopolitical tensions, including trade restrictions, export controls on sequencing technologies and reagents, cross-border data governance clashes, and strained international collaborations, could materially disrupt the growth of North America Genomic Testing Market by constraining supply chains, raising costs, and fragmenting research networks. Restrictions on the import or export of key equipment, consumables, and cloud computing services may cause reagent shortages, longer lead times for instruments, and greater reliance on more expensive domestic or alternative suppliers, squeezing lab margins and slowing test turnaround. Heightened scrutiny over data sharing and differing national rules on genomic data localization or access can inhibit multinational research partnerships and slow the aggregation of diverse reference datasets, which are critical for accurate variant interpretation and equitable test performance.

North America Genomic Testing Market

Segmental Coverage

North America Genomic Testing Market – By Type of Test

North America Genomic Testing Market by type of test is segmented into Diagnostic Testing, Predictive & Presymptomatic Testing, Carrier Testing, Newborn Screening, and Pharmacogenomic Testing. Diagnostic testing is crucial for identifying specific genetic disorders or diseases, enabling prompt and accurate medical intervention. In contrast, predictive and presymptomatic testing evaluates an individual's risk of developing certain diseases, allowing for proactive health management and planning.

North America Genomic Testing Market – By Technology

Based on technology, North America Genomic Testing Market is divided into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Microarray-based Testing segments. PCR is a foundational technique widely used to amplify specific segments of DNA, making it possible to generate millions of copies from a tiny sample, which is crucial for various applications, including diagnostics and research. NGS represents a major leap forward, enabling the rapid sequencing of large volumes of DNA with remarkable efficiency and accuracy. This technology has revolutionized genomics, allowing for comprehensive studies of entire genomes and enhancing our understanding of genetic disorders and complex diseases.

North America Genomic Testing Market - By Sample Type

The sample type segmentation of North America Genomic Testing Market consists of Blood Samples, Saliva Samples, and Tissue Samples segments. Blood samples are the traditional choice for genomic tests due to their reliability and the wealth of information they provide; they are rich in DNA and used extensively for a wide range of testing, including diagnostic and carrier testing. In recent years, saliva samples have gained popularity as a non-invasive alternative, allowing individuals to provide genetic material comfortably and easily at home, making it particularly appealing for consumer genetic testing and ancestry analysis.

North America Genomic Testing Market - By End User

On the basis of end user, North America Genomic Testing Market is divided into Hospitals & Clinics, Laboratories, and Research Institutes segments. Hospitals & clinics are the primary providers of genomic testing services, offering these tests as part of comprehensive healthcare solutions to diagnose and manage genetic conditions. They are often the first point of contact for patients seeking diagnostic or predictive genetic testing, facilitating access to essential information for personalized treatment plans. Laboratories, particularly specialized genomic testing labs, conduct a wide array of tests, employing advanced technologies to analyze genetic material efficiently. These labs are critical for ensuring the accuracy and reliability of test results, as they focus on developing and validating new testing methodologies to meet the needs of healthcare providers.

North America Genomic Testing Market - By Country

The in-depth research report on North America Genomic Testing Market covers the market in the region’s major countries: United States and Canada. United States dominates North America Genomic Testing Market and is also expected to continue its market leadership position during the forecast period. It is primarily due to the United States’ dominant position in the region’s healthcare sector. Meanwhile, Canada is forecast to witness substantial growth in the demand for genomic testing.

Competitive Landscape

Major players operating in the highly competitive North America Genomic Testing Market include Illumina, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies, Inc., Myriad Genetics, Inc., Genomic Health, Inc., 23andMe, Inc., Foundation Medicine, Inc., Color Genomics, Inc., Amgen, Inc., and 24 Genetics. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In February 2026 – Illumina launched its TruPath Genome, a whole-genome sequencing (WGS) tool providing high accuracy.

• In February 2026 – Syndex Bio introduced mcPCR Platform, the methyl-copying PCR technology enabling high-fidelity copying of DNA methylation patterns, for early cancer detection and molecular diagnostics.

Scope of the Report

`

By Type of Test

• Diagnostic Testing

• Predictive and Presymptomatic Testing

• Carrier Testing

• Newborn Screening

• Pharmacogenomic Testing

By Technology

• Polymerase Chain Reaction (PCR)

• Next-Generation Sequencing (NGS)

• Microarray-based Testing

By Sample Type

• Blood Samples

• Saliva Samples

• Tissue Samples

By Application

• Oncology

• Neurology

• Prenatal Testing

• Rare Diseases

By End User

• Hospitals & Clinics

• Laboratories

• Research Institutes